# Bio Key International Inc: financial statements, quarterly

BKYI · Nasdaq · CIK 1019034 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bkyi.md) · [Financials](/companies/bkyi/financials.md) · [Filings](/companies/bkyi/filings.md) · [Insiders](/companies/bkyi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bkyi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,817](/filings/0001437749-25-012824.md) | [1,825 d](/filings/0001437749-25-012824.md) | [2,181](/filings/0001437749-25-017209.md) | [1,141](/filings/0001437749-25-026549.md) | [2,145](/filings/0001437749-25-035227.md) | [1,462 d](/filings/0001437749-26-020446.md) | [1,607](/filings/0001437749-26-021335.md) | [1,697](/filings/0001437749-26-027723.md) | [1,550](/filings/0001437749-25-035227.md) | [1,084 d](/filings/0001437749-26-020446.md) | [2,146](/filings/0001437749-26-021335.md) | [1,920](/filings/0001437749-26-027723.md) |
| Cost of revenue | $k | [1,477](/filings/0001437749-25-012824.md) | [1,921 d](/filings/0001437749-25-012824.md) | [300](/filings/0001437749-25-017209.md) | [262](/filings/0001437749-25-026549.md) | [465](/filings/0001437749-25-035227.md) | [262 d](/filings/0001437749-26-020446.md) | [279](/filings/0001437749-26-021335.md) | [464](/filings/0001437749-26-027723.md) | [358](/filings/0001437749-25-035227.md) | [271 d](/filings/0001437749-26-020446.md) | [376](/filings/0001437749-26-021335.md) | [246](/filings/0001437749-26-027723.md) |
| Gross profit | $k | [341](/filings/0001437749-25-012824.md) | [(95.5) d](/filings/0001437749-25-012824.md) | [1,882](/filings/0001437749-25-017209.md) | [879](/filings/0001437749-25-026549.md) | [1,680](/filings/0001437749-25-035227.md) | [1,200 d](/filings/0001437749-26-020446.md) | [1,328](/filings/0001437749-26-021335.md) | [1,233](/filings/0001437749-26-027723.md) | [1,192](/filings/0001437749-25-035227.md) | [812 d](/filings/0001437749-26-020446.md) | [1,769](/filings/0001437749-26-021335.md) | [1,674](/filings/0001437749-26-027723.md) |
| Research and development | $k | [530](/filings/0001437749-24-035354.md) | [617 d](/filings/0001437749-25-012824.md) | [608](/filings/0001437749-25-017209.md) | [591](/filings/0001437749-25-026549.md) | [652](/filings/0001437749-25-035227.md) | [660 d](/filings/0001437749-26-020446.md) | [596](/filings/0001437749-26-021335.md) | [636](/filings/0001437749-26-027723.md) | [684](/filings/0001437749-25-035227.md) | [694 d](/filings/0001437749-26-020446.md) | [617](/filings/0001437749-26-021335.md) | [640](/filings/0001437749-26-027723.md) |
| Selling, general and administrative | $k | [1,776](/filings/0001437749-24-035354.md) | [2,040 d](/filings/0001437749-25-012824.md) | [1,783](/filings/0001437749-25-017209.md) | [1,942](/filings/0001437749-25-026549.md) | [1,608](/filings/0001437749-25-035227.md) | [1,807 d](/filings/0001437749-26-020446.md) | [1,373](/filings/0001437749-26-021335.md) | [1,681](/filings/0001437749-26-027723.md) | [1,400](/filings/0001437749-25-035227.md) | [1,829 d](/filings/0001437749-26-020446.md) | [1,310](/filings/0001437749-26-021335.md) | [1,563](/filings/0001437749-26-027723.md) |
| Operating income | $k | [(1,966)](/filings/0001437749-25-012824.md) | [(2,724) d](/filings/0001437749-25-012824.md) | [(509)](/filings/0001437749-25-017209.md) | [(1,654)](/filings/0001437749-25-026549.md) | [(580)](/filings/0001437749-25-035227.md) | [(1,268) d](/filings/0001437749-26-020446.md) | [(641)](/filings/0001437749-26-021335.md) | [(1,084)](/filings/0001437749-26-027723.md) | [(892)](/filings/0001437749-25-035227.md) | [(4,211) d](/filings/0001437749-26-020446.md) | [(158)](/filings/0001437749-26-021335.md) | [(529)](/filings/0001437749-26-027723.md) |
| Interest expense | $k | [45.7](/filings/0001437749-23-032644.md) | [58.9 d](/filings/0001437749-24-019357.md) | [1.4](/filings/0001437749-24-020368.md) | [8.9](/filings/0001437749-25-026549.md) | [98.6](/filings/0001437749-25-035227.md) | [66.9 d](/filings/0001437749-26-020446.md) | [35.9](/filings/0001437749-26-021335.md) | [25.6](/filings/0001437749-26-027723.md) | [13.2](/filings/0001437749-25-035227.md) | [(13.9) d](/filings/0001437749-26-020446.md) | [27.2](/filings/0001437749-26-021335.md) | [27.0](/filings/0001437749-26-027723.md) |
| Income tax | $k | [(0.2)](/filings/0001437749-24-035354.md) | [(277) d](/filings/0001437749-25-012824.md) | [0.0](/filings/0001437749-25-017209.md) | [0.0](/filings/0001437749-25-026549.md) | [0.0](/filings/0001437749-25-035227.md) | [(23.0) d](/filings/0001437749-26-020446.md) | [0.0](/filings/0001437749-26-021335.md) | [0.0](/filings/0001437749-26-027723.md) | [0.0](/filings/0001437749-25-035227.md) | [16.5 d](/filings/0001437749-26-020446.md) | [0.0](/filings/0001437749-26-021335.md) | [0.0](/filings/0001437749-26-027723.md) |
| Net income | $k | [(1,838)](/filings/0001437749-25-012824.md) | [(2,373) d](/filings/0001437749-25-012824.md) | [(510)](/filings/0001437749-25-035227.md) | [(1,667)](/filings/0001437749-25-035227.md) | [(739)](/filings/0001437749-25-035227.md) | [(1,384) d](/filings/0001437749-26-020446.md) | [(737)](/filings/0001437749-26-027723.md) | [(1,167)](/filings/0001437749-26-027723.md) | [(965)](/filings/0001437749-25-035227.md) | [(4,289) d](/filings/0001437749-26-020446.md) | [(205)](/filings/0001437749-26-027723.md) | [(577)](/filings/0001437749-26-027723.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(3.22)](/filings/0001437749-25-012824.md) | not reported | [(0.32)](/filings/0001437749-25-017209.md) | [(1.00)](/filings/0001437749-25-026549.md) | [(0.39)](/filings/0001437749-25-035227.md) | not reported | [(1.57)](/filings/0001437749-26-021335.md) | [(2.01)](/filings/0001437749-26-027723.md) | [(0.15)](/filings/0001437749-25-035227.md) | not reported | [(0.20)](/filings/0001437749-26-021335.md) | [(0.56)](/filings/0001437749-26-027723.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001437749-23-032644.md) | [0.5](/filings/0001437749-25-012824.md) | [0.7](/filings/0001437749-24-020368.md) | [1.3](/filings/0001437749-24-026861.md) | [1.8](/filings/0001437749-24-035354.md) | [0.4](/filings/0001437749-26-020446.md) | [3.1](/filings/0001437749-25-017209.md) | [2.3](/filings/0001437749-25-026549.md) | [2.0](/filings/0001437749-25-035227.md) | [2.7](/filings/0001437749-26-027723.md) | [2.2](/filings/0001437749-26-021335.md) | [1.4](/filings/0001437749-26-027723.md) |
| Current assets | $m | [4.0](/filings/0001437749-25-012824.md) | [2.6](/filings/0001437749-25-012824.md) | [2.3](/filings/0001437749-24-020368.md) | [3.0](/filings/0001437749-24-026861.md) | [4.6](/filings/0001437749-24-035354.md) | [1.9](/filings/0001437749-26-020446.md) | [4.6](/filings/0001437749-25-017209.md) | [4.0](/filings/0001437749-25-026549.md) | [3.7](/filings/0001437749-25-035227.md) | [4.5](/filings/0001437749-26-027723.md) | [4.5](/filings/0001437749-26-021335.md) | [3.8](/filings/0001437749-26-027723.md) |
| Total assets | $m | [9.7](/filings/0001437749-23-032644.md) | [4.5](/filings/0001437749-25-012824.md) | [4.2](/filings/0001437749-24-020368.md) | [4.8](/filings/0001437749-24-026861.md) | [6.4](/filings/0001437749-24-035354.md) | [8.6](/filings/0001437749-26-020446.md) | [11.2](/filings/0001437749-25-017209.md) | [10.5](/filings/0001437749-25-026549.md) | [10.1](/filings/0001437749-25-035227.md) | [8.3](/filings/0001437749-26-027723.md) | [8.2](/filings/0001437749-26-021335.md) | [7.5](/filings/0001437749-26-027723.md) |
| Current liabilities | $m | [6.0](/filings/0001437749-23-032644.md) | [3.2](/filings/0001437749-25-012824.md) | [3.3](/filings/0001437749-24-020368.md) | [5.6](/filings/0001437749-24-026861.md) | [5.9](/filings/0001437749-24-035354.md) | [4.6](/filings/0001437749-26-020446.md) | [3.5](/filings/0001437749-25-017209.md) | [3.5](/filings/0001437749-25-026549.md) | [3.0](/filings/0001437749-25-035227.md) | [3.1](/filings/0001437749-26-027723.md) | [3.2](/filings/0001437749-26-021335.md) | [3.0](/filings/0001437749-26-027723.md) |
| Total liabilities | $m | [6.4](/filings/0001437749-23-032644.md) | [3.5](/filings/0001437749-25-012824.md) | [3.6](/filings/0001437749-24-020368.md) | [5.9](/filings/0001437749-24-026861.md) | [6.3](/filings/0001437749-24-035354.md) | [4.8](/filings/0001437749-26-020446.md) | [3.7](/filings/0001437749-25-017209.md) | [3.7](/filings/0001437749-25-026549.md) | [4.1](/filings/0001437749-25-035227.md) | [3.2](/filings/0001437749-26-027723.md) | [3.3](/filings/0001437749-26-021335.md) | [3.1](/filings/0001437749-26-027723.md) |
| Long-term debt | $m | [0.2](/filings/0001437749-23-032644.md) | [0.2](/filings/0001437749-25-012824.md) | [0.1](/filings/0001437749-24-020368.md) | [0.1](/filings/0001437749-24-026861.md) | [0.1](/filings/0001437749-24-035354.md) | [0.0](/filings/0001437749-25-026549.md) | [0.0](/filings/0001437749-25-017209.md) | [0.0](/filings/0001437749-25-026549.md) | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.1](/filings/0001437749-23-032644.md) | [0.1](/filings/0001437749-24-020368.md) | [0.1](/filings/0001437749-24-020368.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [2.3](/filings/0001437749-23-032644.md) | [0.0](/filings/0001437749-24-019357.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(0.5)](/filings/0001437749-25-012824.md) | [1.1](/filings/0001437749-26-020446.md) | [0.5](/filings/0001437749-25-035227.md) | [(1.1)](/filings/0001437749-25-035227.md) | [0.1](/filings/0001437749-25-035227.md) | [3.8](/filings/0001437749-26-027723.md) | [7.5](/filings/0001437749-26-027723.md) | [6.9](/filings/0001437749-26-027723.md) | [6.0](/filings/0001437749-25-035227.md) | [5.1](/filings/0001437749-26-027723.md) | [4.9](/filings/0001437749-26-027723.md) | [4.3](/filings/0001437749-26-027723.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(167) d](/filings/0001437749-24-035354.md) | [(1,532) d](/filings/0001437749-25-012824.md) | [297](/filings/0001437749-25-017209.md) | [(1,421) d](/filings/0001437749-25-026549.md) | [(1,276) d](/filings/0001437749-25-035227.md) | [(515) d](/filings/0001437749-26-020446.md) | [(835)](/filings/0001437749-26-021335.md) | [(880) d](/filings/0001437749-26-027723.md) | [(1,123) d](/filings/0001437749-25-035227.md) | [(1,831) d](/filings/0001437749-26-020446.md) | [(358)](/filings/0001437749-26-021335.md) | [(846) d](/filings/0001437749-26-027723.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-24-035354.md) | [1.0 d](/filings/0001437749-25-012824.md) | [1.9](/filings/0001437749-25-017209.md) | [0.0 d](/filings/0001437749-25-026549.md) | [21.2 d](/filings/0001437749-25-035227.md) | [(10.0) d](/filings/0001437749-26-020446.md) | [4.6](/filings/0001437749-26-021335.md) | [1.5 d](/filings/0001437749-26-027723.md) | [1.3 d](/filings/0001437749-25-035227.md) | [4.6 d](/filings/0001437749-26-020446.md) | [0.0](/filings/0001437749-26-021335.md) | [0.0 d](/filings/0001437749-26-027723.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | period not labelled (2010-06-30) | period not labelled (2011-03-31) | Q2 FY2011 (2011-06-30) | Q1 FY2012 (2012-03-31) | Q2 FY2012 (2012-06-30) | Q1 FY2013 (2013-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [91.0](/filings/0001437749-11-006018.md) | [78.7](/filings/0001437749-12-004876.md) | [78.2](/filings/0001437749-12-008516.md) | [78.2](/filings/0001437749-13-006114.md) | [78.2](/filings/0001437749-12-008516.md) | [81.5](/filings/0001437749-13-006114.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,436,344 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027723.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.